• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

USPSTF Recommends Breast Cancer Screening for Women Aged 40 to 75 Years

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 30, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends breast cancer screening for women aged 40 to 75 years, but evidence is insufficient for older women and for supplemental screening for women with dense breasts. These recommendations form the basis of a final recommendation statement published online April 30 in the Journal of the American Medical Association.

Jillian T. Henderson, Ph.D., M.P.H., from the Kaiser Permanente Evidence-based Practice Center in Portland, Oregon, and colleagues reviewed studies comparing different breast cancer screening strategies. Data were included from seven randomized trials and 13 nonrandomized studies. The researchers observed no mortality difference for screening beyond age 74 years based on a nonrandomized trial emulation study. In a nonrandomized study, advanced cancer detection did not differ following annual or biennial screening intervals. Reduced interval cancer risk but additional false-positive recalls and biopsy results were seen in a randomized clinical trial of individuals with dense breasts undergoing supplemental screening with magnetic resonance imaging. In a modeling study, Amy Trentham-Dietz, Ph.D., from the University of Wisconsin-Madison, and colleagues found that biennial digital breast tomosynthesis starting at age 40 to 74 years was associated with a 30.0 percent reduction in breast cancer mortality. Similar benefits were seen with digital mammography screening, but more false-positive recalls occurred.

Based on these findings, the USPSTF recommends biennial screening mammography for women aged 40 to 74 years (B recommendation), with moderate net benefit. For women aged 75 years or older, the current evidence is insufficient for assessing the balance of benefits and harms of screening mammography (I statement). For women with dense breasts, the current evidence is insufficient for assessing the balance of benefits and harms of supplemental screening with breast ultrasonography or magnetic resonance imaging (I statement).

"We're asking the research community to prioritize studies that can show us how best to screen for breast cancer in women with dense breasts," task force chair Wanda Nicholson, M.D., M.P.H., said in a statement.

Several authors disclosed ties to the pharmaceutical and diagnostics industries.

Evidence Report

Modeling Study

Final Recommendation Statement

Editorial 1

Editorial 2

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.